Wavefront-guided LASIK: a safe treatment for myopia & astigmatism

Article

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism.

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism, according to a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Simon R. Bababeygya and co-workers from Stanford University School of Medicine, Stanford, California, USA conducted a retrospective study which included 89 eyes of 45 patients with moderate (-6.0 to -8.0 D) and high (>-8.00 D) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO). All eyes were analyzed preoperatively and one, three, and 12 months postoperatively.

Mean age was 38.4 years ±7.14 (SD) and no eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10±0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33±0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within ±1.00 D of the intended correction and 64% were within ±0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.

The results of the study confirm that the correction of moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK is both safe and effective.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.